Sex, age below 10 years, post-surgical residual disease, histological subtype, MYC and MYCN amplification, CSI dose reduction, omission of boosts, intensification with myeloablative courses, and presence or absence of metastatic disease did not impact prognosis. The gene discussed is MYCN; the disease is metastatic neoplasm.